ImmuPharma plc (LON:IMM – Get Free Report) rose 9.7% on Friday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.95 ($0.05). Approximately 24,599,076 shares changed hands during trading, an increase of 28% from the average daily volume of 19,273,818 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Performance
The firm has a market capitalization of £17.04 million, a PE ratio of -409.20 and a beta of 1.53. The company’s 50 day simple moving average is GBX 1.71 and its 200-day simple moving average is GBX 1.72.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- How to Use Stock Screeners to Find Stocks
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How to Invest in Small Cap Stocks
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
